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E-mail addresses: wumian@ustc.edu.cn (M. Wu), mARF is the second most commonly inactivated tumor suppressor behind p53. It has been implicated
in the control of cell proliferation, cell senescence, and tumor suppression. However, the detailed
mechanism underlying the transcriptional control of ARF remains largely unknown. Here we report
RUVBL2 as a novel transcriptional repressor of ARF. Ectopic expression of RUVBL2 decreases the lev-
els of ARF, whereas knockdown of RUVBL2 results in a marked increase in ARF levels. In addition,
RUVBL2 down-regulates the levels of p53 in an ARF-dependent manner. Mechanistically, RUVBL2
binds to the distal region of ARF promoter, thus leading to the repression of ARF transcription. These
results suggest an important role of RUVBL2 in the regulation of ARF-p53 pathway.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The ARF (alternate reading frame, p14 in human and p19 in
mouse) tumor suppressor is frequently mutated in human cancers
[1]. ARF has multiple tumor suppressor functions, some of which
are mediated by p53 signaling pathway [2,3]. In this context, ARF
is activated by various oncogenic insults [4,5], which in turn binds
to and inactivates Mdm2. Inactivation of Mdm2 results in the sta-
bilization and activation of p53 [3,6]. Once activated, p53 induces
expression of a large amount of genes, which ultimately leads to
apoptosis, cell cycle arrest, and tumor suppression [7]. In addition
to this p53-dependent tumor suppressor function, ARF also has the
ability to inhibit proliferation in cells lacking p53, or p53 and
mdm2 [2,8]. This p53-independent function of ARF is believed to
be mediated by its binding to various cellular targets, including
E2F1, Myc, HIF1a (hypoxia inducible factor 1, alpha subunit), and
NPM (nucleolar phosphoprotein B23) [9–11].
Given the importance of ARF in tumor suppression, several
stringent control mechanisms have been applied to regulate its
expression level. In primary cells, ARF is subjected to ULF (ubiqui-
tin ligase for ARF)-mediated lysine-independent ubiquitination
and subsequent rapid degradation via proteasome [12]. ARF also
undergoes transcriptional regulation by several molecules. For
example, ectopic expression of E2F1 induces ARF expression by
targeting to a novel E2F-responsive element [13]. A transcription
factor DMP1 has been shown to be recruited to the ARF promoter
region in response to anti-proliferative signals, which leads to thechemical Societies. Published by E
eiyide@ustc.edu.cn (Y. Mei).ARF induction [14]. In addition, it has been reported that Proto-
oncogene Pokemen (FBI-1) directly represses the transcription of
ARF through binding to its promoter, which likely contributes to
the oncogenic transforming ability of FBI-1 [15]. Also, p53 re-
presses ARF expression by recruiting both HDAC (histone deacetyl-
ase) and PcG to the ARF locus [16].
RUVBL1/RUVBL2 (RuvB-like 1/RuvB-like 2) are two highly con-
served members of the AAA+ family (ATPase associated with di-
verse cellular activities) of DNA helicases [17]. In most cases,
RUVBL1 and RUVBL2 form dodecamer and function together in
the same multiprotein complex [18,19]. The RUVBL1/RUVBL2
dodecamer is implicated in variable cellular processes, including
transcription, DNA repair, cellular transformation, cell growth, cell
migration and invasion [20]. Of note, RUVBLs have been exten-
sively studied in the context of transcriptional regulation [21].
The importance of RUVBLs in the transcriptional control is high-
lighted by the fact that RUVBLs participate in the chromatin
remodeling as a member of several complexes such as INO80,
SRCAP, Uril and Tip60 [22–24]. Also, RUVBLs have been reported
to interact physically with a number of transcriptional factors,
including ß-catenin, TBP (TATA-binding protein), Myc, E2F1, ATF2
(activating transcription factor 2) and HIF1a, thereby participating
in the transcriptional control [25–27].
In this study, we report that RUVBL2 is a novel transcriptional
repressor of ARF. Ectopic expression of RUVBL2 results in a
decrease in the levels of ARF, whereas knockdown of RUVBL2
increases ARF levels. Furthermore, RUVBL2 is shown to down-
regulate p53 in an ARF-dependent manner. Our ﬁndings reveal a
novel function of RUVBL2 in controlling ARF transcription and thus
regulating p53 expression.lsevier B.V. All rights reserved.
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2.1. Reagents and plasmids
The following reagents were obtained from the indicated
sources: antibodies against RUVBL2 and p19ARF (Abcam
ab36569, ab80), p14ARF (Calbiochem NA70), GFP (clontech
632375), b-actin and p53 (Santa Cruz Biotechnology sc-81178,
sc-6243), FLAG (Sigma–Aldrich F3165); MG132 (Sigma); Lipofect-
amine 2000 (Invitrogen); complete EDTA free protease inhibitors
(Roche Applied Science).
RUVBL2 expression constructs were made in both pEGFP and
p3FLAG. FBI-1 expression construct was only made in p3FLAG.
The cDNA fragments for the full-length RUVBL2 and FBI-1 were ob-
tained from a human lympho node cDNA library (Clontech) by PCR.
The DNA fragments for various p14ARF promoter regions were
ampliﬁed from genomic DNA isolated from H1299 cells with the35
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Fig. 1. Ectopic expression of RUVBL2 induces p14ARF downregulation independent of pr
of GFP-RUVBL2 or GFP vector. Twenty hours after transfection, cell lysates were subjec
p14ARF was shown. (B) GFP-RUVBL2 or GFP vector was transfected into H1299 cells. T
another 10 h. Cell lysates were analyzed by Western blot. Normalized quantity of p14Afollowing primer pairs: p14ARF (649+73), 50-gatacgcgtcgacagc
tccggcagc-30 and 50-gacaagctttctgcagactgggacccacgcac-30; p14ARF
(649252), 50-gatacgcgtcgacagctccggcagc-30 and 50-gataagctt
gcccaggggccggacg-30; p14ARF (251+73), 50-gatacgcgtcgtcacc
gcggggcg-30 and 50-gacaagctttctgcagactgggacccacgcac-30; p19ARF
promoter regions were ampliﬁed from genomic DNA isolated from
MEF cells with the following primer pairs: 50-gatacgcgtggcgagc
gaagcgagcgggatccggagcgtg-30 and 50-gatagatctcccgctgctgtactccctca
gcggcggcctcactgtgacaag-30. The promoter fragments were then
subcloned into the MluI/HindIII sites of pGL3-basic plasmid.
2.2. Cell culture and transfection
Cell lines H1299, HEK293 T, MEF, and NIH3T3 were cultured in
DMEMmedium containing 10% heat-inactivated fetal bovine serum
(FBS), 1  non-essential amino acid, 100 lg/ml penicillin, 1 MEM
sodium pyruvate, 100 lg/ml streptomycin (Invitrogen) at 37 CGFP
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oteasome. (A) H1299 and HEK293 T cells were transfected with increasing amounts
ted to Western blot analysis with the indicated antibodies. Normalized quantity of
wenty-four hours after transfection, cells were treated with or without MG132 for
RF was shown.
C. Xie et al. / FEBS Letters 586 (2012) 435–441 437under an atmosphere of 5% CO2 in air. Transfection of H1299 and
HEK293 T cells by lipofectamine 2000 (Invitrogen, USA) was
performed according to the methods provided by manufacturer’s
speciﬁcation, which gives 80%–90% transfection efﬁciency. For
transfection of MEF and NIH3T3 cells, the Nucleofector Device
from Amaxa was used to achieve the high transfection efﬁciency
ranging between 70% and 80%.
2.3. RNA interference
To generate retroviruses expressing RUVBL2 and control shR-
NAs, HEK293 T cells grown on 6 cm dish were transfected with
1 lg of pCL-ampho packaging plasmid and either 2 lg of pSU-
PER-retro-puro RUVBL2 shRNAs or control vector. 24 h after
transfection, cells were cultured with DMEM medium containingIB:anti-Flag
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Fig. 2. RUVBL2 suppresses transcription of p14arf. (A) H1299 cells were co-transfected
indicated. Renilla luciferase plasmid pRL-CMV was also introduced as an internal contro
after normalizing with respect to Renilla luciferase activity (mean ± S.D.) (upper panel).
H1299 cells were transfected with increasing amounts of Flag- RUVBL2. Twenty hours aft
actin was used as an internal control. (C) H1299 cells were transfected with increasing am
determined by real time RT-PCR analysis. (D) Total RNAs and Lysates from H1299 cells i
subjected to real time RT-PCR analysis and Western blot analysis, respectively. Normali20% FBS for additional 24 h. The culture medium containing
retrovirus particles was centrifuged at 1000g for 5 min. Viruses
in the supernatant were used for infection. To generate lentivir-
ues expressing p19ARF or control shRNAs, HEK293T cells were
transfected with 2 lg of p19ARF shRNAs (cloned in PLKO.1) or
control vector, 2 lg of pREV, 2 lg of pGag/Pol/PRE, and 1 lg of
pVSVG. 24 h after transfection, cells were cultured with DMEM
medium containing 20% FBS for an additional 24 h. The culture
medium containing lentivirus particles was centrifugated at
1000g for 5 min and then used for infection. The knockdown
efﬁciency was evaluated by Western blot analysis. The shRNA
sequences targeting RUVBL2 are 50-gatgattgagtccctgacc-30
(RUVBL2-shRNA-1) and 50-gaagatgtggagatga gtg-30 (RUVBL2-
shRNA-2). p19ARF targeting shRNA sequence is 50-gaacatgttgttga
ggctagag-30.lag-FBI-1
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with pGL3-p14ARF (649+73) plus Flag-RUVBL2, Flag-FBI-1, or control vector as
l. Thirty-six hours after transfection, luciferase activity was measured and plotted
The levels of Flag-RUVBL2 or Flag-FBI were conﬁrmed by Western blot analysis. (B)
er transfection, the expression of p14ARF was detected by semi-quantitative PCR. ß-
ounts of GFP-RUVBL2. Twenty hours post-transfection, mRNA levels of p14ARF were
ndividually expressing control-shRNA, RUVBL2-shRNA-1, or RUVBL2-shRNA-2 were
zed quantity of p14ARF and RUVBL2 were shown.
438 C. Xie et al. / FEBS Letters 586 (2012) 435–4412.4. Dual-Luciferase Reporter Assay
H1299 cells were transiently transfected with the indicated
luciferase reporter plasmid, together with either Flag-RUVBL2 or
control vector. Renilla plasmid was also included in each transfec-
tion to normalize the transfection efﬁciency. Fireﬂy and Renilla lucif-
erase activities were analyzed by Dual-Luciferase Reporter Assay
system according to the manufacturer’s instructions (Promega).
The relative luciferase activities were calculated by normalizing
the ﬁrely luciferase activity to Renilla luciferase activity. The repre-
sented data were mean ± S.D. of three independent experiments.
2.5. Real-time RT-PCR
Total RNA was isolated using Trizol (Sangon Company, China).
One microgram of RNA was used to synthesize cDNA using
PrimeScript™ RT reagent kit (Takara, DRR037A) according to theA
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Fig. 3. RUVBL2 binds to the distal region of p14ARF promoter. (A) H1299 cells were c
p14ARF (251+73). Thirty-six hours after transfection, luciferase activity was mea
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RUVBL2 were subjected to a ChIP assay using anti-Flag antibody. In this assay, an isotyp
ampliﬁed by PCR using the primers speciﬁc for the promoter region of p14ARF. Ampliﬁmanufacturer’s instruction. Real-time PCR was performed using
SYBR premix EX Taq (TaKaRa) and ROX and analyzed with Strata-
gene Mx3000p (Agilent Technologies). Real-time primer sequences
were as follows: p14ARF 50-ccctcgtgctgatgctactg-30 and 50-cat-
catgacctggtcttctaggaa-30; RUVBL2 50-agatgtggagatgagtgaggac-30
and 50-tgagtagacccgcttgatg-30; b-actin, 50-gacctgactgactacctcatgaa-
gat-30 and 50-gtcacacttcatgatggagttgaagg-30.
2.6. Chromatin immunoprecipitation (ChIP)
ChIP assayswere performed as described previously [28]. Brieﬂy,
H1299 cells expressing Flag-RUVBL2 were ﬁxed with 1% formalde-
hyde and then sonicated to obtain soluble chromatin. After dilution,
the chromatin solutions were incubated with anti-Flag or isotype-
matched control antibody-conjugated protein A/G-Sepharose
beads. After extensive washing, the bound DNA fragments was
eluted and subjected to the PCR ampliﬁcation with the following37+
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gaagaaaggaaagcgaggtc-30; b-actin, 50-gacctgactgactacctcatgaagat-
30 and 50-gtcacacttcatgatggagttgaagg-30.
3. Results
3.1. RUVBL2 is a transcriptional repressor of ARF
To test whether RUVBL2 has any effect on ARF expression, we
transfected the increasing amounts of GFP-RUVBL2 into H1299
and HEK293 T cells. As shown in Fig. 1A, in both cell lines, the
increasing expression of RUVBL2 resulted in the concurrent de-
crease in the levels of endogenous p14ARF. In contrast, knockdown
of RUVBL2 led to the elevated levels of p14ARF (Fig. 2D). We next
examined whether this inhibitory effect of RUVBL2 on p14ARF
expression is proteasome-dependent. To this end, H1299 cells were
transfected with GFP-RUVBL2 or control vector followed by treat-
ment with or without MG132, a proteasome inhibitor. As was
expected, in the absence of MG132, ectopic expression of RUVBL2
markedly decreased levels of p14ARF (Fig. 1B, lane 1 vs 2). MG132
treatment signiﬁcantly increased the basal levels of p14ARFA
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Fig. 4. RUVBL2 regulates p53 levels via ARF. (A) MEF cells were co-transfected with p
luciferase plasmid pRL-CMV was also introduced as an internal control. Thirty-six hour
with respect to Renilla luciferase activity (mean ± S.D.). (B) GFP-RUVBL2 or GFP control ve
lysates were analyzed by Western blot with the indicated antibodies. Normalized quant
expressing p19ARF shRNAs or control shRNAs and retroviruses expressing Flag-RUVBL2
were subjected to Western blot analysis. Asterisk () represents endogenous RUVBL2. p1
cells expressing control-shRNA or RUVBL2-shRNA-2 were subjected to Western blot a
RUVBL2 were shown.(Fig. 1B, lane 3 vs 1), yet it failed to rescue the downregulation of
p14ARF by RUVBL2 (Fig. 1B, lane 4 vs 3). These results suggest that
RUVBL2 down-regulates p14ARF independent of proteasome-med-
iated protein degradation. To further determine whether RUVBL2
represses p14ARF at the transcription level, pGL3-p14ARF
(649+73), a luciferase reporter plasmid containing the promoter
region (649+73) of ARF, was co-transfectedwith Flag-RUVBL2 or
Flag-FBI into H1299 cells. As shown in Fig. 2A, RUVBL2 remarkably
repressed the transcriptional activity of ARF promoter (lane 2 vs 1),
although to a lesser extent comparedwith FBI-1, a potent transcrip-
tional repressor of ARF [14] (lane 2 vs 3). Consistent with its role in
repressing ARF promoter activity, RUVBL2 overexpression de-
creased mRNA levels of p14ARF in a dose-dependent manner
(Fig. 2B and C). However, RUVBL2 knockdown substantially in-
creased p14ARF mRNA levels. Taken together, these results suggest
RUVBL2 as a novel transcriptional repressor of p14ARF.
3.2. RUVBL2 binds to the distal region of p14ARF promoter
Since RUVBL2 represses transcription of p14ARF, we sought to
determine whether RUVBL2 associates with the promoter ofI-1  Flag-RUVBL2
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nalysis with the indicated antibodies. Normalized quantities of p19ARF, p53 and
440 C. Xie et al. / FEBS Letters 586 (2012) 435–441p14ARF, and if so, which region of p14ARF promoter RUVBL2 binds
to. We ﬁrst transfected H1299 cells with Flag-RUVBL2 plus either
pGL3-p14ARF (649252) or pGL3-p14ARF (251+73),
containing the distal or core region of p14ARF promoter accord-
ingly. The subsequent luciferase promoter assay showed that the
transcriptional activity of pGL3-p14ARF (649-252), but not
pGL3-p14ARF (251+73), was greatly inhibited by RUVBL2
(Fig. 3A), indicating that the distal region of p14ARF promoter
may be the potential RUVBL2 target site. We next performed a ChIP
assay to test if RUVBL2 binds to the p14ARF promoter region. As
shown in Fig. 3B, RUVBL2 associated with the distal region of
p14ARF promoter, but not the control ß-actin genomic region. To-
gether, these results suggest that RUVBL2 represses p14ARF gene
transcription though binding to its distal promoter element.
3.3. RUVBL2 regulates p53 levels via ARF
Previous studies have demonstrated the critical role of ARF in
regulating p53 activity. The observation that RUVBL2 represses
ARF expression led us to explore the possibility that RUVBL2 could
down-regulate levels of p53 in an ARF-dependent manner. We ﬁrst
examined whether RUVBL2 inhibits the transcriptional activity of
p19ARF promoter in MEF cells where the ARF-p53 pathway is in-
tact. As was expected, ectopic expression of RUVBL2 markedly
inhibited the promoter activity of p19ARF (Fig. 4A). In MEF cells
with wild-type ARF, RUVBL2 upregulation resulted in the de-
creased levels of p19ARF and p53 (Fig. 4B, lane 2 vs 1 and
Fig. 4C, lane 2 vs 1), whereas knockdown of RUVBL2 led to their en-
hanced expression (Fig. 4D). However, in ARF knockdownMEF cells
or ARF null NIH3T3 cells, overexpression of RUVBL2 failed to show
any noticeable effect on expression of p53 (Fig. 4B, lane 4 vs 3 andC
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Fig. 4 (contFig. 4C, lane 4 vs 3). These results indicate that RUVBL2-mediated
p53 downregulation is ARF dependent and suggest an important
role of RUVBL2 in regulating ARF-p53 pathway.
4. Discussion
As the second-most frequently mutated tumor suppressor in
human cancer, ARF has been shown to control cell proliferation
by activating both p53-dependent and -independent signaling
pathways [2]. In the context of oncogenic stress, ARF is activated
through both transcription-dependent and -independent mecha-
nisms, [5,12] ultimately leading to the activation of p53 and cell
cycle arrest. However, the detailed molecular mechanism underly-
ing transcriptional control of ARF expression remains elusive. In
this study, we identify RUVBL2 as a novel transcriptional repressor
of ARF.
It has long been recognized that RUVBL2 and its homolog
RUVBL1 are involved in the regulation of transcription [21].
RUVBLs are reported to be integral subunits of several different
chromatin remodeling complexes. These complexes function by
increasing nucleosome mobility and inﬂuencing the accessibility
of the underlying DNA, thus regulating gene expression [22–24].
RUVBLs have been also shown to interact with a number of differ-
ent transcriptional factors. For examples, both RUVBL1 and
RUVBL2 can bind ß-catenin and modulate its transcriptional
activity. However these two proteins behave antagonistically, with
RUVBL1 enhancing, and RUVBL2 repressing ß-catenin transcrip-
tional activity [29]. In addition, RUVBL2 cooperates with ß-catenin
and HDAC1 to repress the expression of KAI1, a suppressor of tu-
mor metastasis [30]. RUVBL1 and RUVBL2 also interact with c-
Myc and repress its target gene p21 [31]. More recently, RUVBL1D
Ctrl-sh RUVBL2-sh-2
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mediated histone H2B mono-ubiquitination and promoting PAF1-
mediated histone H3K9 trimethylation [32]. According to the cur-
rent understanding of RUVBs function in transcriptional regulation,
it is not unconceivable that RUVBL2 may repress ARF transcription
by the following possible mechanisms. First, RUVBL2 forms a com-
plex with histone deacetylases, which deacetylates histones and
converts the chromatin into a more compact state, therefore sup-
pressing ARF expression. Second, RUVBL2 functions as part of the
chromatin remodeling complexes that represses ARF transcription
by altering the accessibility of ARF promoter to the transcriptional
machinery. Third, RUVBL2 may repress ARF transcription through
either activating or antagonizing transcriptional factors activity
via direct interaction with them, perhaps with the help of the his-
tone deacetylases.
Numerous studies have demonstrated the critical role of
RUVBL2 in controlling cell growth. Knockdown of RUVBL2 de-
creases cell proliferation in both p53 wild-type and p53 inactive
cells [27,33,34]. Thus our ﬁnding of RUVBL2-mediated repression
of ARF suggests that the function of RUVBL2 in regulating cell pro-
liferation may be partly dependent on ARF. Also, the RUVBL2-ARF
axis may be the key to cell fate determination. Given that p53
pathway has been suggested as an effective target for cancer ther-
apy, the inhibitory effect of RUVBL2 on p53 expression implicates
RUVBL2 as a potential valuable target for therapeutic intervention
in cancer.
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